MarketPulse

clinical trial failure

37 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Mereo BioPharma Faces Securities Lawsuit Over Setrusumab Trial Failures

Securities class action filed against $MREO for allegedly misleading investors about Phase 3 clinical trial results. Lead plaintiff deadline April 6, 2026.
MREOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Mereo BioPharma Faces Securities Class Action Over Setrusumab Trial Failures

Mereo BioPharma faces securities class action for allegedly concealing failed Phase 3 trials for setrusumab. Investors have until April 6, 2026 to act.
MREOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Mereo BioPharma Faces Securities Litigation Over Clinical Trial Disclosures

Mereo BioPharma faces securities lawsuit alleging misrepresentations about Phase 3 trial results for setrusumab, causing investor losses.
SNOWMREOsecurities fraudsecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Claimsfiler

Ultragenyx Investors Face April Deadline in Securities Class Action Over Failed Trial Disclosure

Ultragenyx faces securities lawsuit over delayed disclosure of failed Phase 3 trial. Investors must file lead plaintiff claims by April 6, 2026.
RAREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Vistagen Investors Face Class Action Deadline Following Failed Phase 3 Trial

Vistagen faces class action lawsuit after Phase 3 trial failure for anxiety drug. Stock plunged 80%. Investors must act by March 16, 2026 deadline.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Class Action Cases Launched Against PomDoctor, Vistagen Over Alleged Securities Violations

Class action lawsuits filed against PomDoctor and Vistagen Therapeutics alleging securities violations. Vistagen's stock fell 80% after failed clinical trial results.
VTGNPOMsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Geller Rudman & Dowd Llp

Law Firm Initiates Securities Investigation Into GRAIL Following Failed Cancer Trial

Law firm investigates GRAIL for potential securities violations after cancer trial failure triggered stock decline. Examining whether company adequately disclosed trial risks.
GRALinvestor lossesstock price decline
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Lawsuit Filed Against Mereo BioPharma Over Failed Clinical Trials

Mereo BioPharma faces class action lawsuit over allegedly false statements regarding failed Phase 3 clinical trials. Investors who bought securities between June 2023-December 2025 may be eligible to participate.
MREOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Mereo BioPharma Faces Securities Litigation Over Clinical Trial Disclosures

Mereo BioPharma faces securities litigation alleging it misled investors about Phase 3 clinical trial results for setrusumab, failing to disclose the trials missed primary endpoints.
MREOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Claimsfiler

Ultragenyx Faces Securities Lawsuit Following Setrusumab Trial Failure

Ultragenyx faces securities lawsuit after failing to disclose setrusumab trial failure, causing 42% stock drop. Investors claim company withheld material information before December announcement.
RAREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Investor Lawsuits Filed Against Ultragenyx and Mereo Over Failed Clinical Trials

Class action lawsuits filed against Ultragenyx and Mereo after Phase III clinical trials for setrusumab failed. Stock prices plummeted 42% and 88% respectively following the announcement.
MREORAREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Pomerantz Launches Class Action Against Vistagen Following Failed Trial, Sets March Deadline

Pomerantz launches class action against Vistagen after failed clinical trial caused 80% stock drop. March 16, 2026 deadline for investors to join lawsuit.
SDMVTGNCLEUFsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Mereo BioPharma Faces Class Action Over Failed Clinical Trial Disclosures

Mereo BioPharma faces class action lawsuit over allegedly misleading disclosures about failed Phase 3 clinical trials. Investors who purchased shares between June 2023 and December 2025 may be eligible.
MREOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Mereo BioPharma Faces Securities Lawsuit Over Setrusumab Trial Disclosures

Mereo BioPharma faces securities lawsuit for allegedly making false statements about setrusumab trial results, causing artificially inflated stock prices and investor losses.
MREOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Legal Action Deadline Set for Vistagen Investors Following Failed Trial

Vistagen's failed drug trial caused 81% stock drop. Securities lawsuit filed for investors who bought shares April 2024-December 2025. Lead plaintiff deadline: March 16, 2026.
VTGNsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Mereo BioPharma Investors Face April Deadline in Securities Lawsuit Over Failed Trials

Investors in Mereo BioPharma face April deadline in class action lawsuit alleging executives misrepresented clinical trial results for setrusumab drug, causing stock losses.
MREOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Mereo BioPharma Faces Class Action Over Failed Clinical Trial Disclosures

Mereo BioPharma faces class action lawsuit over allegedly misleading disclosures about failed Phase 3 clinical trials. Investors claim the company concealed negative trial results.
MREOsecurities fraudclass action lawsuit